In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares insights on the method’s key benefits, including how they help to unlock a world of pharmacokinetics knowledge.
Introduction
Making effective decisions based on the data available in drug discovery is challenging. Researchers can’t measure all the activities and properties of every single compound of interest for a drug discovery project – that would be too time-consuming and expensive. In a typical pharma company, only about 1% of the possible data will be available. Even within a project, commonly, only 10-20% of the potential data will have been measured in practice. So, decisions must be made based on incomplete or ‘sparse’ data.
Furthermore, the experimental data that have been measured are noisy. Experiments performed by drug discovery scientists are variable and data will have experimental errors and artefacts. False negatives can lead to missed opportunities, and false positives can mean that time and effort is wasted pursuing hypotheses that later turn out to be based on faulty data. These errors exist, but it’s very difficult to spot them.
Imputation using deep learning is a recent approach applied to drug discovery that addresses these challenges, and is the process of ‘filling in’ missing data based on limited available measurements [1]
About the author
Matt Segall, PhD
CEO, Optibrium
[1] T. Whitehead, B. Irwin, P. S. M. Hunt and G. Conduit, “Imputation of Assay Bioactivity Data Using Deep Learning,” J. Chem. Inf. Model., vol. 59, no. 3, pp. 1197-1204, 2019.
Related content from across the site
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
26th North American ISSX and JSSX Meeting
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Optibrium Appoints James Halle as Chief Commercial Officer
Key appointment brings extensive software commercial experience to drive global growth
